Dr. Reddy's Laboratories has made an investment of $620 million in Dr. Reddys Laboratories SA, Switzerland (DRL SA), a wholly-owned subsidiary of the Company and DRL SA has allotted 6,200,000 non-convertible preference shares each with a nominal value of $100 to the company on September 27, 2024.

The fund infused by the Company into DRL SA will be used by the said wholly-owned subsidiary for the acquisition of Nicotinell and related brands by way of acquisition of all of the quotas of Northstar Switzerland SARL incorporated in Switzerland owned by the Haleon Group.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.